China Approves First Hepatitis D Drug After 13 Years

For nearly 50 years, scientists couldn't crack how hepatitis D infiltrated liver cells, leaving millions without effective treatment options. That mystery is finally solved, and now the first targeted therapy for this aggressive virus has reached patients.

China's National Medical Products Administration approved Libevitug on Friday, a monoclonal antibody that blocks hepatitis B and D viruses from entering liver cells. The drug targets chronic hepatitis D, which only occurs in people already carrying hepatitis B and dramatically accelerates liver damage, cirrhosis, and cancer risk.

The World Health Organization estimates 12 million people globally live with both infections. Until now, treatment options have been painfully limited for what's considered one of the most severe forms of viral hepatitis.

Clinical trial results showed impressive outcomes at 48 weeks. The combined response rate reached 44 percent, with 60 percent of patients showing virological response. Participants saw viral loads drop, liver enzymes normalize, and liver stiffness improve.

Both China's drug regulator and the US Food and Drug Administration had granted Libevitug breakthrough therapy designation, recognizing its potential to address a critical unmet need.

The Ripple Effect

What makes Libevitug exceptional isn't just what it does, but how it came to be. The entire journey happened in China, from fundamental discovery through clinical development.

The story began in 2012 when scientist Li Wenhui and his team identified the specific receptor that allows both viruses to enter liver cells. That discovery answered a question that had stumped researchers worldwide for nearly half a century and opened an entirely new pathway for drug development.

Li partnered with antibody specialist Sui Jianhua to transform that scientific insight into medicine. They developed the prototype antibody in 2015, then founded Huahui Health to shepherd it through clinical trials and toward patients.

This "zero to one, and one to market" approach remains uncommon globally. Most drug development involves multiple handoffs between research institutions and pharmaceutical companies, but this team stayed together through the entire 13-year journey.

The approval arrives as China's innovative drug sector hits its stride. Regulators approved a record 76 innovative drugs in 2025, spanning chemical medicines, biologics, and traditional Chinese medicines. About 70 percent of eligible new drugs approved in early 2025 successfully entered the national reimbursement list, expanding access.

Regulatory reforms including fast-track pathways, breakthrough designations, and conditional approvals have shortened review timelines and reduced uncertainty for developers. The system now supports rapid, cost-efficient drug development backed by strong local ecosystems and talent.

For the millions living with chronic hepatitis D, Libevitug represents something more fundamental than scientific achievement: it represents hope where little existed before.